2 Beaten-Down Healthcare Stocks to Buy and Hold for the Next Decade

The article recommends two undervalued healthcare stocks for long-term investors: HCA Healthcare, which has dropped 13% from its 52-week high despite strong fundamentals and proven resilience through policy changes, and Intuitive Surgical, down 19% this year but maintaining leadership in robotic-assisted surgery with significant growth potential as telesurgery and market expansion opportunities emerge.

10/26/2026, 10:30 AM • The Motley Fool

Breakfast News: Week in Review

Meta, SpaceX, and Tesla posted strong revenue but are spending heavily on AI infrastructure with uncertain cash flow outcomes. Walmart opened AI shopping to approved agents while Amazon blocked them. Salesforce acquired Braze for a 58% premium but analysts expect modest returns. Netflix and Intuitive Surgical face pricing power challenges. Old-economy companies like Cisco, Corning, and EQT benefit from AI buildout demand.

10/23/2026, 7:30 AM • The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood's Ark Invest added to positions in Netflix, Oklo, and Intuitive Surgical on Wednesday, all of which have declined significantly over the past year. Netflix hit a two-year low after disappointing guidance, Oklo has surrendered 86% from its peak despite promising nuclear technology, and Intuitive Surgical faces competitive threats but maintains strong earnings beats.

10/22/2026, 11:41 AM • The Motley Fool

Abbott: 3 Key Takeaways for Long-Term Investors

Abbott announced plans to spin off its nutrition business into an independent public company, focusing on higher-margin medical technologies and diagnostics. The company reported 7% year-over-year comparable sales growth in Q3 2026, with cancer diagnostics sales up 14% driven by Cologuard and new blood-based colorectal cancer screening tests. Pulsed field ablation technology is accelerating growth in electrophysiology, positioning Abbott for accelerated growth beyond historical rates.

10/21/2026, 4:15 PM • The Motley Fool

Breakfast News: A $5.7 Billion Flex or Genius?

Salesforce acquires Braze for $5.7 billion to strengthen its marketing capabilities, with Braze stock jumping 50%. Netflix faces growth challenges with slowing revenue and weak ad performance. SpaceX beats expectations with 161% revenue growth, while Intuitive Surgical falls despite beating estimates due to cooling U.S. procedure growth. Tesla, Meta, and IBM report earnings with major capital spending decisions in focus. EQT continues steady cash flow growth as a natural gas producer.

10/21/2026, 7:30 AM • The Motley Fool

Breakfast News: A One-Line Fix Could Shake Up AI

Amazon released TorchNeuron, an open-source software tool that allows PyTorch code to run on AWS Trainium chips with minimal changes, challenging Nvidia's market dominance. Amazon stock surged 5% on the announcement. Meanwhile, Karooooo's shares fell 8% despite strong subscriber growth due to lower-than-expected earnings and unchanged guidance. Netflix and SpaceX are set to report earnings, with Netflix focusing on ad revenue growth and SpaceX on AI spending efficiency. MercadoLibre continues expanding in Latin America with heavy investments in shipping and payments.

10/20/2026, 7:30 AM • The Motley Fool

3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case.

Three Wall Street analysts have $500 price targets for Intuitive Surgical, citing strong growth in robot-assisted surgery procedures and the rollout of the da Vinci 5 platform. The company benefits from a recurring revenue model through instruments and accessories, with procedures growing 15% year-over-year. However, the stock's high P/E ratio of ~49 leaves limited room for disappointment.

10/19/2026, 9:30 AM • The Motley Fool

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

Abbott Laboratories and Intuitive Surgical represent different healthcare investment strategies. Abbott offers diversified operations across diagnostics, nutrition, and medical devices with a conservative 18x forward P/E ratio, $7.4B free cash flow, and 2.49% dividend yield. Intuitive Surgical commands a premium 39x P/E multiple but delivers 21% revenue growth, zero debt, and dominance in robotic-assisted surgery. Both companies project ~13% sales growth for 2026, but Abbott's lower valuation and new Cologuard cancer screening acquisition make it the better buy for long-term value investors.

10/12/2026, 2:40 PM • The Motley Fool

4 Healthcare Stocks Worth Owning for the Next Decade

The article recommends four healthcare stocks across two key niches: GLP-1 weight-loss drugs (Eli Lilly and Novo Nordisk) and surgical robotics (Intuitive Surgical and Medtronic). Eli Lilly leads in GLP-1 but faces patent expiration risks, while Novo Nordisk is a turnaround story with attractive valuation. Intuitive Surgical dominates surgical robotics with strong recurring revenue, while Medtronic offers a diversified play with dividend appeal as it launches its Hugo surgical robot.

10/12/2026, 11:15 AM • The Motley Fool

Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors Expect

Johnson & Johnson is positioned for faster growth by 2030 following its separation from its slower-growing consumer health division. The company can now focus investments on its faster-growing biopharma and medtech segments. Key growth drivers include recent drug approvals like ICOTYDE and the FDA-cleared Ottava robotic surgery system, which operates in a market with significant expansion potential. Despite challenges from government price negotiations and talc-related lawsuits, J&J's diversified portfolio and strong dividend history make it an attractive long-term investment.

10/08/2026, 10:05 AM • The Motley Fool

2 Beaten-Down Stocks to Buy Before They Bounce Back

Shopify and Intuitive Surgical, despite significant year-to-date declines of 19% and 29% respectively, present attractive buying opportunities. Shopify's strong Q2 results and AI-powered initiatives position it well in e-commerce, while Intuitive Surgical's market leadership in robotic-assisted surgery and high switching costs provide competitive advantages despite increased competition from Medtronic.

09/22/2026, 6:33 PM • The Motley Fool

Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?

Medtronic's stock is down 3% this year despite strong fundamentals, presenting a buying opportunity for growth-oriented investors. The company's Hugo robotic-assisted surgery system is gaining traction and eroding competitor Intuitive Surgical's market dominance. With Q1 FY2027 revenue up 13.7% YoY, raised full-year guidance, a near-Dividend King status (49 consecutive years of dividend increases), and attractive valuation metrics, analysts view the stock as undervalued compared to peers.

09/17/2026, 3:23 PM • The Motley Fool

Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning?

Intuitive Surgical's stock has declined 40% from recent highs amid slowing da Vinci robot sales growth due to increased competition from Medtronic and Johnson & Johnson. However, the company's core business model relies on recurring revenue from parts and services (75% of revenue), which provides stable annuity-like income streams. With valuation metrics below five-year averages and continued AI opportunities, the stock may represent a buying opportunity for aggressive growth investors despite its historical volatility.

09/05/2026, 3:15 PM • The Motley Fool

2 Stocks Down 8% or More That Are Screaming Buys Right Now

The article highlights two beaten-down stocks as potential buying opportunities: Intuitive Surgical, down 34% year-to-date, is positioned to benefit from its da Vinci 5 surgical system's advanced features and expanding market; Novo Nordisk, down 8% this year, has promising GLP-1 pipeline candidates like amycretin and UBT251 that could help it regain market share in the weight-loss drug sector.

09/04/2026, 10:30 AM • The Motley Fool

3 Stocks Whose Competitive Walls Tower Over Nvidia's

While Nvidia has built a strong competitive moat in AI chips, three healthcare stocks—Moderna, Intuitive Surgical, and Vertex Pharmaceuticals—possess even more formidable competitive advantages. Moderna leverages its mRNA expertise across vaccines and oncology; Intuitive Surgical dominates robotic surgery with high switching costs; and Vertex leads in cystic fibrosis treatment with a patent-protected pipeline extending to the late 2030s.

09/03/2026, 11:10 AM • The Motley Fool